Solventum Corporation $SOLV Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY decreased its position in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 20.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 160,000 shares of the company’s stock after selling 40,000 shares during the period. Solventum makes up about 3.3% of Clark Estates Inc. NY’s investment portfolio, making the stock its 11th biggest position. Clark Estates Inc. NY’s holdings in Solventum were worth $14,104,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. WINTON GROUP Ltd acquired a new stake in shares of Solventum during the second quarter valued at about $3,402,000. Squarepoint Ops LLC lifted its stake in shares of Solventum by 6,103.8% in the second quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock worth $18,757,000 after acquiring an additional 239,209 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Solventum in the second quarter worth about $150,066,000. Lone Peak Global Investors LLC lifted its stake in shares of Solventum by 38.5% in the second quarter. Lone Peak Global Investors LLC now owns 433,128 shares of the company’s stock worth $33,416,000 after acquiring an additional 120,352 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Solventum in the second quarter valued at about $1,018,000.

Solventum Stock Down 2.7%

NYSE:SOLV opened at $86.23 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.72 and a current ratio of 1.03. The company has a market capitalization of $14.64 billion, a price-to-earnings ratio of 96.89, a price-to-earnings-growth ratio of 1.26 and a beta of 0.69. Solventum Corporation has a one year low of $62.38 and a one year high of $94.16. The stock has a 50-day simple moving average of $87.39 and a 200 day simple moving average of $79.06.

Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.11. Solventum had a return on equity of 25.03% and a net margin of 1.91%. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter in the prior year, the firm posted $1.50 earnings per share. Solventum’s revenue for the quarter was down 7.0% compared to the same quarter last year. Sell-side analysts predict that Solventum Corporation will post 7.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SOLV. Wells Fargo & Company upped their target price on Solventum from $89.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th. Canadian Imperial Bank of Commerce set a $35.00 price target on shares of Solventum in a research report on Wednesday, October 28th. Mizuho set a $113.00 price target on shares of Solventum in a research note on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Finally, Weiss Ratings downgraded shares of Solventum from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $90.27.

Check Out Our Latest Stock Analysis on Solventum

Solventum Profile

(Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Recommended Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.